An exceptional case of severe combined inherited thrombophilia successfully treated with rivaroxaban.

Abstract

: We herein report the case of a young patient who presented with premature thromboembolic venous disease secondary to combined heterozygous G20210A prothrombin mutation, dual homozygosity for Factor V Leiden, and severe protein S deficiency. This association has never been reported to date and is likely to be exceptional, even in populations wherein these thrombophilia traits are more common. Long-term antithrombotic prophylaxis with rivaroxaban has proven successful in preventing clinical recurrence under prolonged treatment.

• Authors: Evelien Krumb, Cédric Hermans
• Journal: Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis (Blood Coagul Fibrinolysis) Vol. 31 Issue 4 Pg. 279-282 (Jun 2020) ISSN: 1473-5733 [Electronic] England
• PMID: 32108680 (Publication Type: Case Reports, Journal Article)

Chemical References

• Factor Xa Inhibitors
• Rivaroxaban

Topics

• Child
• Factor Xa Inhibitors (pharmacology, therapeutic use)
• Humans
• Male
• Risk Factors
• Rivaroxaban (pharmacology, therapeutic use)
• Thrombophilia (drug therapy)